euro adhoc: MediGene AG / MediGene Receives Approval for the Three-Months Sustained Release Product Eligard® (previously known as Leuprogel®) (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

Martinsried - San Diego, January 26, 2004: The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has received marketing authorization for Germany from the Bundesinstitut für Arzneimittel und Medizinprodukte (= Federal Institute for pharmaceuticals and medical devices), BfArM, for the three-months sustained release product of the anti-cancer drug Eligard® (previously known as Leuprogel®) for the treatment of advanced prostate cancer. The corresponding one-month sustained release product of this drug had received marketing authorization at the beginning of December 2003. The three-months sustained release product offers additional applications of Eligard®, thus enhancing its competitiveness. As announced on January 14, MediGene's partner Yamanouchi will take on market launch and sale of Eligard®. As part of the agreement with Yamanouchi, MediGene will receive a milestone payment for this approval of the three-months sustained release product.

MediGene and Yamanouchi are planning to submit marketing authorization applications in other European countries as well. Within the framework of the so-called "Mutual Recognition Procedure", the German approval will serve as a reference there. MediGene had acquired the license for commercialization of Eligard® in Europe from the US company Atrix Laboratories, Inc. in April 2001.

Contact:
MediGene AG, Email: investor@medigene.com, Fax: ++49-89-8565-2920 Julia Hofmann, Public Relations, ph.: ++49-89-8565-3324
Dr. Michael Nettersheim, Investor Relations, ph.:++49-89-8565-2946

Further inquiry note:
Jessica Kern
Tel.: +49 (0)89 8565 2986
E-mail: j.kern@medigene.com
Tel: +49 (0)89 8565 2900
FAX: +49 (0)89 8565 2920
Email: investor@medigene.com

Emittent: MediGene AG Lochhamer Str. 11 DE-82152 Martinsried Tel: +49 (0)89 8565 2900 FAX: +49 (0)89 8565 2920 Email: investor@medigene.com WWW: www.medigene.de ISIN: DE0005020903 WKN: 502090

end of announcement euro adhoc

Indizes: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: regulated dealing Frankfurter Wertpapierbörse; free trade Niedersächsische Börse zu Hannover, Berliner Wertpapierbörse, Bayerische Börse, Hamburger Wertpapierbörse, Bremer Wertpapierbörse (BWB), Börse Düsseldorf, Baden-Württembergische Wertpapierbörse Branche: Biotechnology
Sprache: Englisch

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0002